T-knife Launches Phase 1 Trial of CRISPR T Cell Therapy - Top-Institutions - MDSpire

T-knife Launches Phase 1 Trial of CRISPR T Cell Therapy

The first-in-human ATLAS trial will test PRAME-targeting CRISPR T cells in advanced cancers

  • March 16, 2026

  • 2 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Immuno-oncology
    • Cellular Therapy
    • Gene Editing

  • #2

    University of Pennsylvania (Perelman School of Medicine)
    University of Pennsylvania (Perelman School of Medicine)

    Philadelphia, PA

    Key Differentiators

    • Cellular Immunotherapy
    • Gene Editing
    • Oncology

  • #3

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Immunotherapy
    • Gene Editing
    • Oncology

  • #4

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Immuno-oncology
    • Gene Editing
    • Cellular Therapy

  • #5

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Cancer Immunotherapy
    • Gene Editing
    • Clinical Trials

Original Source(s)

T-knife Launches Phase 1 Trial of CRISPR T Cell Therapy

  • March 16, 2026

Related Content

Long-term results after surgical resection of intrahepatic cholangiocarcinoma before and since the BILCAP era

Clinical utility of an optoelectronic imaging tracing system for diagnosis of high-grade cervical lesions

Development and validation of an interpretable machine learning model for predicting 5-year recurrence in breast cancer